Partnering in Retinal Health
Our goal is to transform the retinal health landscape by developing new treatments and technologies to prevent vision loss in people at risk of, and preserve or restore vision in those already with, retinal diseases. Collaborations with academic institutions and biotech partners connect our scientists with experts and enable us to accelerate the delivery of much-needed new treatments. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners in retinal health.
Our experience
We have a strong foundation in research in diabetic retinopathies and are applying knowledge and insights from oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. This means we have the ability to tackle the multifactorial pathophysiology of retinal diseases to address the serious medical need for effective treatment for eye diseases.
Our research focus
Our research takes a holistic approach, targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and inflammation. We are pursuing both oral and intravitreal treatments as part of an innovative pre-clinical and clinical portfolio grounded in these mechanisms. We are also exploring opportunities in gene therapy to help us deliver therapeutic advances in our core indications:
- Geographic atrophy
- Wet age-related macular degeneration
- Diabetic macular ischemia
- Non-proliferative diabetic retinopathy
- Stargardt disease.
Our partnering interests
Our partnering interests offer various opportunities for collaboration, with other companies and academic institutions, to complement our pipeline and advance treatment and delivery. Read our flyer to find out more.
Related Content
